| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10018400 | HBV | ENSG00000091513.16 | protein_coding | TF | No | No | 7018 | A0PJA6 P02787 Q06AH7 |
| TVIS10018557 | HBV | ENSG00000091513.16 | protein_coding | TF | No | No | 7018 | A0PJA6 P02787 Q06AH7 |
| TVIS10018401 | HBV | ENSG00000091513.16 | protein_coding | TF | No | No | 7018 | A0PJA6 P02787 Q06AH7 |
| TVIS10017821 | HBV | ENSG00000091513.16 | protein_coding | TF | No | No | 7018 | A0PJA6 P02787 Q06AH7 |
| TVIS10025157 | HBV | ENSG00000091513.16 | protein_coding | TF | No | No | 7018 | A0PJA6 P02787 Q06AH7 |
| TVIS10029380 | HBV | ENSG00000091513.16 | protein_coding | TF | No | No | 7018 | A0PJA6 P02787 Q06AH7 |
| TVIS10019016 | HBV | ENSG00000091513.16 | protein_coding | TF | No | No | 7018 | A0PJA6 P02787 Q06AH7 |
| TVIS10018750 | HBV | ENSG00000091513.16 | protein_coding | TF | No | No | 7018 | A0PJA6 P02787 Q06AH7 |
| TVIS10018853 | HBV | ENSG00000091513.16 | protein_coding | TF | No | No | 7018 | A0PJA6 P02787 Q06AH7 |
| TVIS10018722 | HBV | ENSG00000091513.16 | protein_coding | TF | No | No | 7018 | A0PJA6 P02787 Q06AH7 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | TF |
|---|---|
| DrugBank ID | DB01592 |
| Drug Name | Iron |
| Target ID | BE0000510 |
| UniProt ID | P02787 |
| Regulation Type | |
| PubMed IDs | 21049900 |
| Citations | Ha-Duong NT, Eid C, Hemadi M, El Hage Chahine JM: In vitro interaction between ceruloplasmin and human serum transferrin. Biochemistry. 2010 Dec 7;49(48):10261-3. doi: 10.1021/bi1014503. Epub 2010 Nov 9. |
| Groups | Approved |
| Direct Classification | Homogeneous transition metal compounds |
| SMILES | [Fe] |
| Pathways | Cerivastatin Action Pathway; Oxidation of Branched-Chain Fatty Acids; Simvastatin Action Pathway; Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2); Galactosemia III; Smith-Lemli-Opitz Syndrome (SLOS); Tyrosine Metabolism; Zellweger Syndrome; Hereditary Coproporphyria (HCP); Hypercholesterolemia; Glucose-6-phosphate Dehydrogenase Deficiency; Mevalonic Aciduria; Porphyrin Metabolism; Tryptophan Metabolism; Taurine and Hypotaurine Metabolism; Pentose Phosphate Pathway; Inositol Metabolism; Catecholamine Biosynthesis; Phenylketonuria; Vitamin A Deficiency; Congenital Erythropoietic Porphyria (CEP) or Gunther Disease; Cystinosis, Ocular Nonnephropathic; Pyrimidine Metabolism; Congenital Disorder of Glycosylation CDG-IId; Lovastatin Action Pathway; Nucleotide Sugars Metabolism; Aromatic L-Aminoacid Decarboxylase Deficiency; Cysteine Metabolism; Galactose Metabolism; The Oncogenic Action of Fumarate |
| PharmGKB | PA450087 |
| ChEMBL |
